To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma
Background: Endometrial cancer is one of the most commonly diagnosed cancers in women worldwide. Aim and Objectives: To study the expression of estrogen receptor (ER), progesterone receptor (PR) and p53 immunohistochemistry (IHC) markers in subtyping endometrial carcinoma. Materials and Methods: A t...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
Series: | Indian Journal of Pathology and Microbiology |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/ijpm.ijpm_568_22 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832591242039394304 |
---|---|
author | Anuja Yadav Anuradha Sistla Meenakshi Swain Swarnalata Gowrishankar Michelle de Padua Tejal Modi Rallabandi Himabindu Neha Agarwal Aditya Kulkarni Trilok Bhandari Hemanth Vudayaraju Chinnababu Vijay A. Reddy |
author_facet | Anuja Yadav Anuradha Sistla Meenakshi Swain Swarnalata Gowrishankar Michelle de Padua Tejal Modi Rallabandi Himabindu Neha Agarwal Aditya Kulkarni Trilok Bhandari Hemanth Vudayaraju Chinnababu Vijay A. Reddy |
author_sort | Anuja Yadav |
collection | DOAJ |
description | Background:
Endometrial cancer is one of the most commonly diagnosed cancers in women worldwide.
Aim and Objectives:
To study the expression of estrogen receptor (ER), progesterone receptor (PR) and p53 immunohistochemistry (IHC) markers in subtyping endometrial carcinoma.
Materials and Methods:
A total of 100 cases of carcinoma endometrium submitted during January 2016 to October 2018 were included in our study. The ER, PR and p53 expressions were scored as per the adopted scoring system. Agreement between ER, PR and p53 IHC expression and the consensus HE diagnosis, FIGO grading and tumour staging were assessed using Chi square tests.
Results:
There was a statistical association between ER, PR and p53 status and tumour histologic type with a P value < 0.01. There was no statistical significance observed between ER and PR expressions and different FIGO grades. Statistical significance (P = 0.036) between p53 and different FIGO grades seen. No statistical significance was observed between ER, PR and p53 expressions and different tumour stages and tumour invasiveness. There was a statistical association between ER and PR status and lymph node metastasis. p53 did not show a statistical significance.
Conclusion:
Combination of ER, PR and p53 IHC markers can be used to distinguish type 1 and type 2 endometrial cancers. PR expression is more specific than ER in endometrioid carcinomas. p53 expression is more specific in serous carcinoma, however, p53 IHC alone cannot be used to distinguish different grades of endometrioid carcinomas as there is variability of staining in endometrioid carcinomas. |
format | Article |
id | doaj-art-82f0f01ccd2c43d985a6aee74b0d5b35 |
institution | Kabale University |
issn | 0377-4929 0974-5130 |
language | English |
publishDate | 2023-07-01 |
publisher | Wolters Kluwer Medknow Publications |
record_format | Article |
series | Indian Journal of Pathology and Microbiology |
spelling | doaj-art-82f0f01ccd2c43d985a6aee74b0d5b352025-01-22T15:09:10ZengWolters Kluwer Medknow PublicationsIndian Journal of Pathology and Microbiology0377-49290974-51302023-07-01671626710.4103/ijpm.ijpm_568_22To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinomaAnuja YadavAnuradha SistlaMeenakshi SwainSwarnalata GowrishankarMichelle de PaduaTejal ModiRallabandi HimabinduNeha AgarwalAditya KulkarniTrilok BhandariHemanth VudayarajuChinnababuVijay A. ReddyBackground: Endometrial cancer is one of the most commonly diagnosed cancers in women worldwide. Aim and Objectives: To study the expression of estrogen receptor (ER), progesterone receptor (PR) and p53 immunohistochemistry (IHC) markers in subtyping endometrial carcinoma. Materials and Methods: A total of 100 cases of carcinoma endometrium submitted during January 2016 to October 2018 were included in our study. The ER, PR and p53 expressions were scored as per the adopted scoring system. Agreement between ER, PR and p53 IHC expression and the consensus HE diagnosis, FIGO grading and tumour staging were assessed using Chi square tests. Results: There was a statistical association between ER, PR and p53 status and tumour histologic type with a P value < 0.01. There was no statistical significance observed between ER and PR expressions and different FIGO grades. Statistical significance (P = 0.036) between p53 and different FIGO grades seen. No statistical significance was observed between ER, PR and p53 expressions and different tumour stages and tumour invasiveness. There was a statistical association between ER and PR status and lymph node metastasis. p53 did not show a statistical significance. Conclusion: Combination of ER, PR and p53 IHC markers can be used to distinguish type 1 and type 2 endometrial cancers. PR expression is more specific than ER in endometrioid carcinomas. p53 expression is more specific in serous carcinoma, however, p53 IHC alone cannot be used to distinguish different grades of endometrioid carcinomas as there is variability of staining in endometrioid carcinomas.https://journals.lww.com/10.4103/ijpm.ijpm_568_22endometrial carcinomaestrogen receptorprogesterone receptorp53subtypes |
spellingShingle | Anuja Yadav Anuradha Sistla Meenakshi Swain Swarnalata Gowrishankar Michelle de Padua Tejal Modi Rallabandi Himabindu Neha Agarwal Aditya Kulkarni Trilok Bhandari Hemanth Vudayaraju Chinnababu Vijay A. Reddy To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma Indian Journal of Pathology and Microbiology endometrial carcinoma estrogen receptor progesterone receptor p53 subtypes |
title | To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma |
title_full | To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma |
title_fullStr | To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma |
title_full_unstemmed | To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma |
title_short | To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma |
title_sort | to study the expression of estrogen progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma |
topic | endometrial carcinoma estrogen receptor progesterone receptor p53 subtypes |
url | https://journals.lww.com/10.4103/ijpm.ijpm_568_22 |
work_keys_str_mv | AT anujayadav tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT anuradhasistla tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT meenakshiswain tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT swarnalatagowrishankar tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT michelledepadua tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT tejalmodi tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT rallabandihimabindu tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT nehaagarwal tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT adityakulkarni tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT trilokbhandari tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT hemanthvudayaraju tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT chinnababu tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma AT vijayareddy tostudytheexpressionofestrogenprogesteronereceptorandp53immunohistochemistrymarkersinsubtypingendometrialcarcinoma |